Blueprint Medicines Corp Stock Current Valuation
| BPMC Stock | USD 96.62 1.81 1.91% |
Valuation analysis of Blueprint Medicines Corp helps investors to measure Blueprint Medicines' intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns. The current year's Enterprise Value is expected to grow to about 2.1 B, whereas Enterprise Value Over EBITDA is projected to grow to (12.59). Fundamental drivers impacting Blueprint Medicines' valuation include:
Price Book 19.6005 | Enterprise Value 5.9 B | Enterprise Value Ebitda (11.22) | Price Sales 14.129 | Enterprise Value Revenue 13.5244 |
Fairly Valued
Today
Please note that Blueprint Medicines' price fluctuation is very steady at this time. Calculation of the real value of Blueprint Medicines Corp is based on 3 months time horizon. Increasing Blueprint Medicines' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Blueprint Medicines is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Blueprint Stock. However, Blueprint Medicines' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 96.62 | Real 94.28 | Target 74.65 | Hype 96.62 | Naive 88.08 |
The real value of Blueprint Stock, also known as its intrinsic value, is the underlying worth of Blueprint Medicines Corp Company, which is reflected in its stock price. It is based on Blueprint Medicines' financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Blueprint Medicines' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Blueprint Medicines Corp helps investors to forecast how Blueprint stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Blueprint Medicines more accurately as focusing exclusively on Blueprint Medicines' fundamentals will not take into account other important factors: Blueprint Medicines Corp Company Current Valuation Analysis
Blueprint Medicines' Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Blueprint Medicines Current Valuation | 5.88 B |
Most of Blueprint Medicines' fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Blueprint Medicines Corp is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Blueprint Current Valuation Driver Correlations
Understanding the fundamental principles of building solid financial models for Blueprint Medicines is extremely important. It helps to project a fair market value of Blueprint Stock properly, considering its historical fundamentals such as Current Valuation. Since Blueprint Medicines' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Blueprint Medicines' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Blueprint Medicines' interrelated accounts and indicators.
Click cells to compare fundamentals
Blueprint Current Valuation Historical Pattern
Today, most investors in Blueprint Medicines Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Blueprint Medicines' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's current valuation growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Blueprint Medicines current valuation as a starting point in their analysis.
Blueprint Medicines Current Valuation |
| Timeline |
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Blueprint Medicines Corp has a Current Valuation of 5.88 B. This is 59.1% lower than that of the Biotechnology sector and 26.47% higher than that of the Health Care industry. The current valuation for all United States stocks is 64.66% higher than that of the company.
Blueprint Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Blueprint Medicines' direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Blueprint Medicines could also be used in its relative valuation, which is a method of valuing Blueprint Medicines by comparing valuation metrics of similar companies.Blueprint Medicines is currently under evaluation in current valuation category among its peers.
Blueprint Medicines ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Blueprint Medicines' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Blueprint Medicines' managers, analysts, and investors.Environmental | Governance | Social |
Blueprint Fundamentals
| Return On Equity | -0.5 | ||||
| Return On Asset | -0.15 | ||||
| Profit Margin | (0.29) % | ||||
| Operating Margin | (0.38) % | ||||
| Current Valuation | 5.88 B | ||||
| Shares Outstanding | 63.53 M | ||||
| Shares Owned By Insiders | 0.90 % | ||||
| Shares Owned By Institutions | 99.10 % | ||||
| Number Of Shares Shorted | 4.13 M | ||||
| Price To Earning | 7.93 X | ||||
| Price To Book | 19.60 X | ||||
| Price To Sales | 14.13 X | ||||
| Revenue | 249.38 M | ||||
| Gross Profit | 177.28 M | ||||
| EBITDA | (474.61 M) | ||||
| Net Income | (506.98 M) | ||||
| Cash And Equivalents | 853.11 M | ||||
| Cash Per Share | 14.28 X | ||||
| Total Debt | 774.12 M | ||||
| Debt To Equity | 0.14 % | ||||
| Current Ratio | 6.00 X | ||||
| Book Value Per Share | 4.93 X | ||||
| Cash Flow From Operations | (436.85 M) | ||||
| Short Ratio | 6.53 X | ||||
| Earnings Per Share | (2.09) X | ||||
| Target Price | 125.58 | ||||
| Number Of Employees | 638 | ||||
| Beta | 0.59 | ||||
| Market Capitalization | 6.14 B | ||||
| Total Asset | 1.05 B | ||||
| Retained Earnings | (2.34 B) | ||||
| Working Capital | 593.47 M | ||||
| Current Asset | 170.42 M | ||||
| Current Liabilities | 18.64 M | ||||
| Net Asset | 1.05 B |
About Blueprint Medicines Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Blueprint Medicines Corp's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Blueprint Medicines using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Blueprint Medicines Corp based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Blueprint Medicines Corp offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Blueprint Medicines' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Blueprint Medicines Corp Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Blueprint Medicines Corp Stock:Check out Blueprint Medicines Piotroski F Score and Blueprint Medicines Altman Z Score analysis. You can also try the Top Crypto Exchanges module to search and analyze digital assets across top global cryptocurrency exchanges.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Blueprint Medicines. If investors know Blueprint will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Blueprint Medicines listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.09) | Revenue Per Share 6.986 | Quarterly Revenue Growth 1.266 | Return On Assets (0.15) | Return On Equity (0.50) |
The market value of Blueprint Medicines Corp is measured differently than its book value, which is the value of Blueprint that is recorded on the company's balance sheet. Investors also form their own opinion of Blueprint Medicines' value that differs from its market value or its book value, called intrinsic value, which is Blueprint Medicines' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Blueprint Medicines' market value can be influenced by many factors that don't directly affect Blueprint Medicines' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Blueprint Medicines' value and its price as these two are different measures arrived at by different means. Investors typically determine if Blueprint Medicines is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Blueprint Medicines' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.